PSA Levels of 0.07-0.08 ng/mL After Radical Prostatectomy Do Not Meet the Standard Definition of Biochemical Recurrence and Should Be Monitored Closely
These PSA values are below the AUA-defined threshold for biochemical recurrence (≥0.2 ng/mL confirmed by a subsequent value ≥0.2 ng/mL), but they warrant close surveillance rather than immediate intervention. 1
Understanding the Biochemical Recurrence Definition
The American Urological Association established a standardized definition after reviewing 53 different definitions used across 145 studies. Biochemical recurrence after radical prostatectomy is defined as an initial PSA value ≥0.2 ng/mL followed by a subsequent confirmatory PSA value ≥0.2 ng/mL. 1 This threshold was selected as the most commonly used definition (appearing in 35 of the reviewed studies) and represents the optimal balance between sensitivity and specificity for predicting clinical disease progression. 2
Your PSA values of 0.08 and 0.07 ng/mL fall below this threshold and therefore do not constitute biochemical recurrence by current standards.
Clinical Significance of Low Detectable PSA
While these values don't meet recurrence criteria, they're not entirely reassuring either:
- Patients with detectable PSA >0.2 ng/mL have a very high risk (64-93% at 1-3 years) of progression to higher PSA levels 3
- However, the guideline specifically chose 0.2 ng/mL rather than lower thresholds (like 0.1 ng/mL) because lower cutpoints increase sensitivity but decrease specificity 2
- A cutpoint of 0.4 ng/mL followed by another increase may better predict metastatic relapse risk, though 0.2 ng/mL remains the standard for defining recurrence 1
Recent research suggests that ultra-sensitive PSA measurements can identify patients at risk earlier, but this hasn't changed the standard definition. One 2026 study found that patients with PSA ≥0.03 ng/mL with subsequent increases had a 5-year recurrence-free survival of only 63.8%, particularly concerning in high-risk patients. 4 Another 2024 study showed that patients with PSA <0.02 ng/mL at 5 years post-surgery had a 98.5% 10-year recurrence-free survival. 5
Recommended Management Approach
For your situation with PSA values of 0.07-0.08 ng/mL:
Confirm the trend with repeat PSA testing in 3 months 6
- If PSA continues to rise and reaches ≥0.2 ng/mL with confirmation, this would meet biochemical recurrence criteria
- If PSA remains stable or decreases, continue surveillance
Consider your risk stratification factors 6:
- PSA every 3 months initially to establish trend
- If stable, can extend to every 6 months
- Digital rectal examination and imaging only if PSA rises to meet recurrence criteria
When to Consider Early Intervention
Do not initiate salvage therapy at these PSA levels. 6 However, if PSA rises to ≥0.2 ng/mL with confirmation:
- Early salvage radiotherapy (at PSA <0.5 ng/mL) is associated with better outcomes than waiting for higher PSA levels 8, 6
- The 2024 AUA/ASTRO/SUO guideline emphasizes not waiting for arbitrary PSA thresholds once the decision for salvage therapy is made 6
- Consider PSMA-PET imaging if PSA reaches recurrence threshold to guide treatment planning 8, 6
Critical Pitfalls to Avoid
- Don't treat based on ultra-sensitive PSA values alone without confirming a rising trend 6
- Don't assume these low values represent benign residual tissue without serial monitoring - approximately 11% of post-prostatectomy patients develop PSA-only recurrence 9
- Don't order extensive imaging (bone scan, CT) at these PSA levels - risk of detecting metastases is <3% even with PSA >30 ng/mL when PSADT >6 months 7
Your current PSA values require vigilant monitoring but not immediate treatment. Establish the trend over the next 3-6 months with serial PSA measurements.